Genelux Co. (NASDAQ:GNLX) Major Shareholder Aladar Szalay Sells 48,683 Shares

Genelux Co. (NASDAQ:GNLX) major shareholder Aladar Szalay sold 48,683 shares of the stock in a transaction that occurred on Tuesday, April 16th. The shares were sold at an average price of $3.53, for a total value of $171,850.99. Following the transaction, the insider now owns 1,322,862 shares of the company’s stock, valued at $4,669,702.86. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Genelux Stock Up 6.8 %

GNLX traded up $0.24 during trading on Thursday, reaching $3.86. The company had a trading volume of 107,520 shares, compared to its average volume of 123,095. The business has a 50 day simple moving average of $6.36 and a 200-day simple moving average of $11.70. Genelux Co. has a 52 week low of $3.42 and a 52 week high of $40.98.

Institutional Trading of Genelux

A number of institutional investors have recently bought and sold shares of the stock. Woodward Diversified Capital LLC lifted its position in Genelux by 2,326.2% in the fourth quarter. Woodward Diversified Capital LLC now owns 1,082,270 shares of the company’s stock worth $15,163,000 after buying an additional 1,037,663 shares during the last quarter. Vanguard Group Inc. increased its stake in Genelux by 1.8% in the fourth quarter. Vanguard Group Inc. now owns 998,810 shares of the company’s stock worth $13,993,000 after purchasing an additional 17,817 shares during the period. Provident Wealth Management LLC purchased a new stake in Genelux in the third quarter worth $8,211,000. AE Wealth Management LLC increased its stake in Genelux by 1,370.0% in the third quarter. AE Wealth Management LLC now owns 194,875 shares of the company’s stock worth $4,772,000 after purchasing an additional 181,618 shares during the period. Finally, Northern Trust Corp increased its stake in Genelux by 2.0% in the fourth quarter. Northern Trust Corp now owns 164,083 shares of the company’s stock worth $2,299,000 after purchasing an additional 3,267 shares during the period. 37.33% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. HC Wainwright lowered their target price on Genelux from $35.00 to $32.00 and set a “buy” rating for the company in a research report on Tuesday, April 2nd. Benchmark reiterated a “speculative buy” rating and set a $30.00 target price on shares of Genelux in a research report on Wednesday, April 3rd.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.